<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798586</url>
  </required_header>
  <id_info>
    <org_study_id>C1071002</org_study_id>
    <nct_id>NCT04798586</nct_id>
  </id_info>
  <brief_title>MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma</brief_title>
  <official_title>A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and tolerability of elranatamab&#xD;
      (PF-06863135) in Japanese participants with relapsed or refractory MM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">April 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Number of participants with DLTs, which are typically Grade 3 or higher adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of treatment-emergent adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>type and severity (including severity per NCI CTCAE v5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of laboratory abnormalities</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>complete blood count and serum chemistry; type and severity of abnormalities (severity per NCI CTCAE v5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of PF-06863135</measure>
    <time_frame>4 weeks</time_frame>
    <description>Peak concentration of elranatamab (PF-06863135)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of PF-06863135</measure>
    <time_frame>approximately every 1 to 3 cycles (approximately 2 years)</time_frame>
    <description>Incidence and titers of anti-drug antibodies and neutralizing antibodies against elranatamab (PF-06863135)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>approximately every 3 weeks for approximately 2 years</time_frame>
    <description>overall response rate (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>approximately every 3 weeks (approximately 2 years)</time_frame>
    <description>time to response (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>approximately every 3 weeks (approximately 2 years)</time_frame>
    <description>duration of response (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>approximately every 3 weeks (approximately 2 years)</time_frame>
    <description>progression free survival (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>approximately every 3 months (approximately 2 years)</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimal residual disease</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>minimal residual disease (IMWG MRD criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic soluble immune factors</measure>
    <time_frame>approximately 9 months</time_frame>
    <description>pre and post dose quantification of soluble cytokines in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-06863135</measure>
    <time_frame>4 weeks</time_frame>
    <description>AUC of elranatamab (PF-06863135)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentrations of PF-06863135</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Trough concentrations of (PF-06863135)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Elranatamab (PF-06863135)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCMA-CD3 bispecific antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elranatamab (PF-06863135)</intervention_name>
    <description>BCMA-CD3 bispecific antibody</description>
    <arm_group_label>Elranatamab (PF-06863135)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma (IMWG criteria)&#xD;
&#xD;
          -  Measurable disease, as defined by at least 1 of the following&#xD;
&#xD;
               1. Serum myeloma (M) protein ≥0.5 g/dL (5 g/L)&#xD;
&#xD;
               2. Urine M protein ≥200 mg/24 h&#xD;
&#xD;
               3. Serum free light chain (FLC) &gt;100 mg/L (10 mg/dL) with abnormal kappa:lambda&#xD;
                  ratio&#xD;
&#xD;
          -  Participants must have progressed on or been intolerant of at least 3 prior therapies&#xD;
             including proteasome inhibitor, IMID drug and anti-CD38 antibody, either in&#xD;
             combination or as a single agent&#xD;
&#xD;
          -  ECOG PS 0, 1 or 2. PS 3 is permitted if PS is due solely to bone pain&#xD;
&#xD;
          -  Adequate bone marrow, hematological, kidney and liver function&#xD;
&#xD;
          -  Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1&#xD;
&#xD;
          -  Not pregnant and willing to use contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  POEMS syndrome&#xD;
&#xD;
          -  Any other active malignancy within 3 years prior to enrollment, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or carcinoma in situ&#xD;
&#xD;
          -  History of active autoimmune disorders&#xD;
&#xD;
          -  Any form of primary immunodeficiency&#xD;
&#xD;
          -  History of severe immune-mediated adverse event with prior immunomodulatory treatment&#xD;
&#xD;
          -  Stem cell transplant within 12 weeks prior to enrollment&#xD;
&#xD;
          -  Active graft versus host disease other than Grade 1 skin involvement, or that&#xD;
             requiring immunosuppressive treatment&#xD;
&#xD;
          -  Requirement for systemic immune suppressive medication&#xD;
&#xD;
          -  Active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, known&#xD;
             HIV or AIDS related illness and SARS-CoV2&#xD;
&#xD;
          -  Previous administration with an investigational drug within 4 weeks or 5 half-lives&#xD;
             preceding the first dose of study intervention used in this study (whichever is&#xD;
             longer)&#xD;
&#xD;
          -  Known or suspected hypersensitivity to component of elranatamab (PF-06863135), murine&#xD;
             and bovine products&#xD;
&#xD;
          -  Live attenuated vaccine within 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C1071002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

